Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jose Ramón Sanchez de la Torre"'
Autor:
Javier Riancho, Pablo Fdez-Arroyabe, Lucía Paz-Fajardo, Jose Ramón Sanchez de la Torre, Ana Santurtún, Michal Cifra, Kostas Kourtidis, Cristina Limia
Publikováno v:
International Journal of Biometeorology. 65:107-117
The term neurodegenerative diseases include a long list of diseases affecting the nervous system that are characterized by the degeneration of different neurological structures. Among them, Alzheimer disease (AD), Parkinson disease (PD), and amyotrop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b054b7cf00e72c0fd971dd30a8647954
https://doi.org/10.1007/s00484-020-01896-y
https://doi.org/10.1007/s00484-020-01896-y
Autor:
Yesica Jiménez-López, Lara Pardina-Vilella, Jose Ramón Sanchez de la Torre, Javier Riancho, Pascual Sánchez-Juan
Publikováno v:
Journal of the Neurological Sciences. 372:468-470
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3baa603e1cc8aa963d74d2b00cdcd4a0
https://doi.org/10.1016/j.jns.2016.11.002
https://doi.org/10.1016/j.jns.2016.11.002
Autor:
Pilar Santiago-Setien, Cristina Barquín-Rego, Paula Hernández-Martínez, María Ezquerra-Marigomez, Marta Torres-Barquin, Cristina Menéndez-Garcia, Fernando Uriarte, Yésica Jiménez-López, Mercedes Misiego, Jose Ramón Sánchez de la Torre, Sonia Setien, Manuel Delgado-Alvarado, Javier Riancho
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
We aimed to assess the long-term safety and effectiveness of ocrelizumab in a cohort of patients with multiple sclerosis (MS) at high risk of progressive multifocal leukoencephalopathy (PML), previously treated with natalizumab in extending interval
Externí odkaz:
https://doaj.org/article/083009cfbb7d4593b4e22a370e70576c
Autor:
Javier Riancho, Sonia Setien, Jose Ramón Sánchez de la Torre, Marta Torres-Barquin, Mercedes Misiego, José Luis Pérez, Tamara Castillo-Triviño, Cristina Menéndez-García, Manuel Delgado-Alvarado
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
The extended interval dosing (EID) of natalizumab has been suggested to be associated with a reduced risk of progressive multifocal leukoencephalopathy (PML) and short-term preservation of efficacy but its long-term effectiveness remain unknown. We a
Externí odkaz:
https://doaj.org/article/8ac4cc2f742247e9a04d5e9c13ea7c41